Parambir Dulai

Parambir S. Dulai, MD, is a board-certified gastroenterologist with clinical and research expertise in inflammatory bowel disease (IBD). Dr. Dulai is a proud recipient of the 2022 Sherman Emerging Leader Prize by The Bruce and Cynthia Sherman Charitable Foundation that recognizes outstanding achievements in IBD. He is an Associate Professor of Medicine at Northwestern University where he also serves as Director of Precision Medicine for the Division of Gastroenterology and Hepatology. Dr. Dulai completed his medical school training at Dayanand Medical College in Ludhiana, Punjab, India, and subsequently completed his internal medicine residency and chief residency at Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. He then went on to complete an NIH sponsored T32 research fellowship and IBD clinical fellowship at the University of California San Diego, La Jolla, CA, USA. He spent an additional year of advanced training in clinical trials with Robarts Clinical Trials and in 2019 he was the recipient of the American Gastroenterology Association (AGA) research scholar award focused on personalized medicine. He has a successful NIH funded research program focused on real world evidence generation, clinical trials, and integrating evolving translational technology into mechanism of action studies.

David Choi completed his Doctor of Pharmacy degree at the University of Colorado School of Pharmacy. He went on to complete his PGY1 Pharmacy Residency and PGY2 Ambulatory residency at The Johns Hopkins Hospital. He is currently an Associate Director at University of Chicago Medicine Inflammatory Bowel Disease Center. He is very excited about advocating for increased pharmacists’ role in gastroenterology/hepatology as well as importance for patient advocacy in receiving the care they require. He feels passionately about treat to target to improve patient care and research related to improving patient outcomes.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Parambir S. Dulai, MD, is a board-certified gastroenterologist with clinical and research expertise in inflammatory bowel disease (IBD). Dr. Dulai is a proud recipient of the 2022 Sherman Emerging Leader Prize by The Bruce and Cynthia Sherman Charitable Foundation that recognizes outstanding achievements in IBD. He is an Associate Professor of Medicine at Northwestern University where he also serves as Director of Precision Medicine for the Division of Gastroenterology and Hepatology. Dr. Dulai completed his medical school training at Dayanand Medical College in Ludhiana, Punjab, India, and subsequently completed his internal medicine residency and chief residency at Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. He then went on to complete an NIH sponsored T32 research fellowship and IBD clinical fellowship at the University of California San Diego, La Jolla, CA, USA. He spent an additional year of advanced training in clinical trials with Robarts Clinical Trials and in 2019 he was the recipient of the American Gastroenterology Association (AGA) research scholar award focused on personalized medicine. He has a successful NIH funded research program focused on real world evidence generation, clinical trials, and integrating evolving translational technology into mechanism of action studies.

Parambir S. Dulai, MD, is a board-certified gastroenterologist with clinical and research expertise in inflammatory bowel disease (IBD). Dr. Dulai is a proud recipient of the 2022 Sherman Emerging Leader Prize by The Bruce and Cynthia Sherman Charitable Foundation that recognizes outstanding achievements in IBD. He is an Associate Professor of Medicine at Northwestern University where he also serves as Director of Precision Medicine for the Division of Gastroenterology and Hepatology. Dr. Dulai completed his medical school training at Dayanand Medical College in Ludhiana, Punjab, India, and subsequently completed his internal medicine residency and chief residency at Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. He then went on to complete an NIH sponsored T32 research fellowship and IBD clinical fellowship at the University of California San Diego, La Jolla, CA, USA. He spent an additional year of advanced training in clinical trials with Robarts Clinical Trials and in 2019 he was the recipient of the American Gastroenterology Association (AGA) research scholar award focused on personalized medicine. He has a successful NIH funded research program focused on real world evidence generation, clinical trials, and integrating evolving translational technology into mechanism of action studies.

Payal Kakadiya received her Doctor of Pharmacy from the University of Georgia College of Pharmacy. She went on to complete a PGY-1 Pharmacy Practice Residency and PGY-2 Internal Medicine Pharmacy Residency at VCU Health. Payal is a board-certified pharmacotherapy specialist who started off her career practicing at VCU Health as one of the clinical pharmacy specialists on Internal Medicine services as well as the inpatient Digestive Health service and outpatient GI and Medicine Infusion Clinic. She has now transitioned into her role as the Clinical Pharmacist Practitioner in the GI/IBD Clinics at UNC Health.

Edward V. Loftus, Jr. is a gastroenterologist who specializes in the care of patients with complex Crohn's disease and ulcerative colitis. He is the Maxine and Jack Zarrow Family Professor of Gastroenterology Specifically in IBD at Mayo Clinic College of Medicine and Science in Rochester, Minnesota, USA. He developed a population-based cohort of inflammatory bowel disease patients which has resulted in over 50 peer-reviewed publications on the epidemiology and natural history of IBD. Professor Loftus has published over 500 original articles, book chapters, or editorials and more than 750 abstracts. He was awarded AGA’s Distinguished Clinician Award and the IMIBD section’s Research Mentor Award in 2019. He has also been awarded the Mayo Department of Medicine Laureate Award twice and the Outstanding Mentorship Award in Research. Professor Loftus has been the principal investigator on several funded studies focusing on the epidemiology and natural history of inflammatory bowel disease and has served as the local PI on multiple clinical trials of investigational agents for IBD. He serves on the steering committees of several clinical development programs in IBD. In the past he has served as Associate Editor for American Journal of Gastroenterology and Inflammatory Bowel Diseases, and currently serves as Associate Editor for Clinical Gastroenterology and Hepatology.

Parambir S. Dulai, MD, is a board-certified gastroenterologist with clinical and research expertise in inflammatory bowel disease (IBD). Dr. Dulai is a proud recipient of the 2022 Sherman Emerging Leader Prize by The Bruce and Cynthia Sherman Charitable Foundation that recognizes outstanding achievements in IBD. He is an Associate Professor of Medicine at Northwestern University where he also serves as Director of Precision Medicine for the Division of Gastroenterology and Hepatology. Dr. Dulai completed his medical school training at Dayanand Medical College in Ludhiana, Punjab, India, and subsequently completed his internal medicine residency and chief residency at Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. He then went on to complete an NIH sponsored T32 research fellowship and IBD clinical fellowship at the University of California San Diego, La Jolla, CA, USA. He spent an additional year of advanced training in clinical trials with Robarts Clinical Trials and in 2019 he was the recipient of the American Gastroenterology Association (AGA) research scholar award focused on personalized medicine. He has a successful NIH funded research program focused on real world evidence generation, clinical trials, and integrating evolving translational technology into mechanism of action studies.

Dr. Grossman is the Associate Clinic Chief of Gastroenterology, Hepatology, and Nutrition and Co-Director of the Center for Pediatric Inflammatory Bowel Disease at the Children’s Hospital of Philadelphia and the Robert N. Baldassano MD Professor of Clinical Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Grossman has dedicated his career to advancing the quality of clinical care and promoting a multidisciplinary approach for children and adolescents with IBD. He has led national committees for the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and ImproveCareNow (ICN). He has been involved with the Crohn’s & Colitis Foundation for years, serving on the Board of Directors and the Chapter Medical Advisory Committee for the Philadelphia/Delaware Valley chapter, as well as serving as chair of the Pediatric Affairs Committee on the National Scientific Advisory Committee (NSAC). He has co-authored multiple research publications, is an editor of the Pediatric Inflammatory Bowel Disease textbook, and frequently lectures at national scientific meetings.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Dr. Cohen is a Staff Physician and Co-Section Head and Clinical Director for Inflammatory Bowel Diseases in the Department of Gastroenterology, Hepatology, and Nutrition at the Cleveland Clinic, Cleveland, OH. Throughout his career, Dr. Cohen has merged clinical care with participation in inflammatory bowel disease (IBD) clinical research. His primary research interest has been centered on the safety of biologic medications in the peri-operative period for which he led PUCCINI, a large multi-center clinical study. Dr. Cohen has also been a site primary investigator on Phase 3 IBD pharmaceutical clinical trials and collaborative investigator initiated studies. In addition to his research interests, Dr. Cohen also has a strong commitment to IBD education. He has been a member of the Crohn’s & Colitis Foundation Professional Education Committee and a co-founder and former chair of Rising Educators Academics and Clinicians Helping IBD (REACH-IBD); a special committee within the Crohn’s & Colitis Foundation of America for trainees and junior faculty to promote collaboration, mentorship, and career advancement. The Crohn’s and Colitis Foundation recognized him for his leadership with the Rising Star award in 2018. He currently serves on the Crohn's and Colitis Foundation NSAC as the Chair of Professional Membership. Dr. Cohen has also been an active member of the American Gastroenterological Association (AGA) serving on both the Education and Training Committee and Clinical Guidelines Committee.

Parambir S. Dulai, MD, is a board-certified gastroenterologist with clinical and research expertise in inflammatory bowel disease (IBD). Dr. Dulai is a proud recipient of the 2022 Sherman Emerging Leader Prize by The Bruce and Cynthia Sherman Charitable Foundation that recognizes outstanding achievements in IBD. He is an Associate Professor of Medicine at Northwestern University where he also serves as Director of Precision Medicine for the Division of Gastroenterology and Hepatology. Dr. Dulai completed his medical school training at Dayanand Medical College in Ludhiana, Punjab, India, and subsequently completed his internal medicine residency and chief residency at Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA. He then went on to complete an NIH sponsored T32 research fellowship and IBD clinical fellowship at the University of California San Diego, La Jolla, CA, USA. He spent an additional year of advanced training in clinical trials with Robarts Clinical Trials and in 2019 he was the recipient of the American Gastroenterology Association (AGA) research scholar award focused on personalized medicine. He has a successful NIH funded research program focused on real world evidence generation, clinical trials, and integrating evolving translational technology into mechanism of action studies.

Phillip R. Fleshner, MD is the Director of Colorectal Surgery Research at Cedars-Sinai Medical Center. He holds the Shierley, Jesslyne, and Emmeline Widjaja Chair in Colorectal Surgery.

Dr. Fleshner's main clinical and research interests are directed towards optimizing outcomes and techniques in the surgical management of Crohn's disease and ulcerative colitis.

Dr. Fleshner has written numerous articles for peer-reviewed publications, including the Annals of Surgery, Journal of the American College of Surgeons, Diseases of the Colon and Rectum, Gut and the American Journal of Surgery.

Dr. Fleshner received his bachelor's degree from McGill University and his medical degree from the Albert Einstein College of Medicine. He completed his General Surgery Residency at the Mount Sinai Medical Center in New York and his Colorectal Surgery Fellowship at the Lahey Clinic in Boston.

He received the Sherman Prize in 2021.

Dr. Christina Ha completed her internal medicine residency and fellowship at the Washington University in St. Louis School of Medicine and then received additional training as the Present-Levison Inflammatory Bowel Diseases Fellow at the Mount Sinai School of Medicine. She is Director of the Inflammatory Bowel Disease Section and Associate Professor of Medicine at Mayo Clinic Arizona. Her clinical research interests focus on the impact of aging on the natural history of the inflammatory bowel diseases, especially the pathogenesis and natural history of late-onset IBD. She is also very involved in IBD related trainee educational initiatives and has served on multiple committees within the Crohn’s and Colitis Foundation, American College of Gastroenterology, and American Gastroenterological Association.